Bluebird bio to sell to investment funds after struggling to make money from gene therapies
A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out of time and options. The company has struggled financially even as it ...
A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out of time and options.
The company has struggled financially even as it ...
